Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) (UROCOR)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01284608
First received: January 26, 2011
Last updated: December 21, 2012
Last verified: December 2012

January 26, 2011
December 21, 2012
March 2011
December 2012   (final data collection date for primary outcome measure)
  • Metabolic syndrome [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Metabolic syndrome [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Metabolic syndrome [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Diabetes [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Diabetes [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Diabetes [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01284608 on ClinicalTrials.gov Archive Site
Fracture Risk Assessment Tool (FRAx) assessment [ Time Frame: 0 and 12 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Prostate cancer patients in androgen-ablaction treatment in urological departments

Prostatic Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
197
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
  • Provision of informed consent prior to conducting any study-related procedure

Exclusion Criteria:

  • Patient involved in a Clinical Trial
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01284608
NIS-OES-DUM-2010/1
No
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP